These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 19741508

  • 21. Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.
    Harenberg J, Ingrid J, Tivadar F.
    Isr Med Assoc J; 2002 Nov; 4(11):1003-5. PubMed ID: 12489490
    [Abstract] [Full Text] [Related]

  • 22. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C, Mouret P.
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [Abstract] [Full Text] [Related]

  • 23. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D, Boucher M.
    Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
    [Abstract] [Full Text] [Related]

  • 24. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) trial.
    Tangelder MJ, Frison L, Weaver D, Wilcox RG, Bylock A, Emanuelsson H, Held P, Oldgren J.
    Am Heart J; 2008 Feb; 155(2):382-7. PubMed ID: 18215612
    [Abstract] [Full Text] [Related]

  • 34. Discovery of ximelagatran in an historical perspective.
    Gustafsson D.
    Semin Vasc Med; 2005 Aug; 5(3):227-34. PubMed ID: 16123909
    [Abstract] [Full Text] [Related]

  • 35. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M, Sarich TS, Eriksson UG.
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [Abstract] [Full Text] [Related]

  • 36. Ximelagatran: direct thrombin inhibitor.
    Ho SJ, Brighton TA.
    Vasc Health Risk Manag; 2006 Aug; 2(1):49-58. PubMed ID: 17319469
    [Abstract] [Full Text] [Related]

  • 37. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL.
    Rev Cardiovasc Med; 2004 Aug; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
    Petersen P, Grind M, Adler J, SPORTIF II Investigators.
    J Am Coll Cardiol; 2003 May 07; 41(9):1445-51. PubMed ID: 12742279
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.